📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Morphotek

1.1 - Company Overview

Morphotek Logo

Morphotek

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of gene evolution-based monoclonal antibody products to treat cancer, inflammation, and infectious diseases. Offerings include RESPECT-H+L conjugation technology enabling dual payload delivery with in vivo ADC tracking, and an Eribulin ADC payload with cytotoxic effects on receptor-positive and neighboring receptor-negative tumor cells.

Products and services

  • Monoclonal Antibody Discovery and Development: Uses gene evolution technology to develop novel biological-based mAbs targeting cancer, inflammation, and infectious diseases, advancing discovery and development since 2000, gene-evolution–driven
  • RESPECT-H+L: Conjugation technology enabling dual payload delivery with two mechanisms of action, simultaneous delivery of two cytotoxins to the same cell, and in vivo ADC tracking, dual-payload
  • Eribulin ADC Payload: Exhibits cytotoxic effects on receptor-positive and neighboring receptor-negative tumor cells and induces vascular remodeling and mesenchymal-to-epithelial transition in tumors, ADC-integrated

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Morphotek

Dermira Logo

Dermira

HQ: United States Website
  • Description: Provider of specialty biopharmaceutical development and commercialization of innovative dermatology therapies. Focused on bringing differentiated products to dermatologists and patients, with a portfolio of five product candidates. Founded in 2010, headquartered in Menlo Park, California.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Dermira company profile →
Abcuro Logo

Abcuro

HQ: United States Website
  • Description: Provider of immunotherapies for autoimmunity and cancer, including ABC008, a monoclonal antibody targeting KLRG1 to selectively deplete highly cytotoxic T cells in inclusion body myositis, T-cell large granular lymphocytic leukemia, and certain cancers, and ABC015, a preclinical antibody blocking KLRG1-ligand interaction to activate cytotoxic T and NK cells; conducts clinical trials for ABC008 in IBM and T-LGLL.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Abcuro company profile →
Curevo Vaccine Logo

Curevo Vaccine

HQ: United States Website
  • Description: Provider of next-generation, non-mRNA vaccines for infectious diseases, developing Amezosvatein for the prevention of shingles and chickenpox.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Curevo Vaccine company profile →
Luminary Therapeutics Logo

Luminary Therapeutics

HQ: United States Website
  • Description: Provider of preclinical cell therapies for cancer and autoimmune diseases, including the Allogeneic Gamma 2.0+ platform for B-cell malignancies; Split Co-Stim Dual CAR targeting multiple solid tumor antigens, designed to enhance persistence and prevent T cell exhaustion; BAFF ligand-based CAR addressing BAFF, BCMA, and TACI to mitigate antigen escape; and a non-viral TcBuster transposon process for cost-efficient CAR-T manufacturing.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Luminary Therapeutics company profile →
Alligator Bioscience Logo

Alligator Bioscience

HQ: Sweden Website
  • Description: Provider of antibody-based immunotherapies for cancer, including next-generation CD40 agonists and bispecific CD40-targeting antibodies, developed using its FIND® (Fragment INduced Diversity) protein optimization technology, and discovering and developing drug candidates up to phase IIa clinical studies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Alligator Bioscience company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Morphotek

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Morphotek

2.2 - Growth funds investing in similar companies to Morphotek

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Morphotek

4.2 - Public trading comparable groups for Morphotek

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Morphotek

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Morphotek

What does Morphotek do?

Morphotek is a provider of gene evolution-based monoclonal antibody products to treat cancer, inflammation, and infectious diseases. Offerings include RESPECT-H+L conjugation technology enabling dual payload delivery with in vivo ADC tracking, and an Eribulin ADC payload with cytotoxic effects on receptor-positive and neighboring receptor-negative tumor cells.

Who are Morphotek's competitors?

Morphotek's competitors and similar companies include Dermira, Abcuro, Curevo Vaccine, Luminary Therapeutics, and Alligator Bioscience.

Where is Morphotek headquartered?

Morphotek is headquartered in United States.

How many employees does Morphotek have?

Morphotek has 1,000 employees 🔒.

When was Morphotek founded?

Morphotek was founded in 2010 🔒.

What sector and industry vertical is Morphotek in?

Morphotek is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Morphotek

Who are the top strategic acquirers in Morphotek's sector and industry

Top strategic M&A buyers and acquirers in Morphotek's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Morphotek?

Top strategic M&A buyers groups and sectors for Morphotek include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Morphotek's sector and industry vertical

Which are the top PE firms investing in Morphotek's sector and industry vertical?

Top PE firms investing in Morphotek's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Morphotek's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Morphotek's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Morphotek's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Morphotek include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Morphotek's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Morphotek?

The key public trading comparables and valuation benchmarks for Morphotek include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Morphotek for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Morphotek with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Morphotek's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Morphotek with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Morphotek's' sector and industry vertical?

Access recent funding rounds and capital raises in Morphotek's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Morphotek